Previous 10 | Next 10 |
2024-03-12 14:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for ORIC on March 12, 2024 12:55PM ET. The previous analyst recommendation was Outperform. ORIC was trading at $14.62 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-03-12 14:00:02 ET David Nierengarten from Wedbush issued a price target of $20.00 for ORIC on 2024-03-12 12:55:00. The adjusted price target was set to $20.00. At the time of the announcement, ORIC was trading at $14.63. The overall price target consensus is at $7.0...
2024-03-11 17:01:32 ET More on ORIC Pharmaceuticals Cantor starts ORIC at overweight, cites potential of ORIC-114 ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will present a company ove...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts have been accepted...
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is the focus of IBN's latest stock spotlight. The company's shares have moved 11.46% on the day to $14.2. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's p...
2024-02-23 16:23:17 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...
SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat...
News, Short Squeeze, Breakout and More Instantly...
Oric Pharmaceuticals Inc. Company Name:
ORIC Stock Symbol:
NASDAQ Market:
Oric Pharmaceuticals Inc. Website:
2024-06-13 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 04:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best...